MyMedR

Displaying publications 21 - 24 of 24 in total

Abstract:

Sort:

Achilles in Ukraine: Concerns and priorities over the long-term implications of trauma

Matiashova L, Tsagkaris C, Essar MY, Romash IB, Vus VI

Int J Health Plann Manage, 2022 11;37(6):3369-3371.
PMID: 36030526 DOI: 10.1002/hpm.3562
Matched MeSH terms: Ukraine
Fulltext The genus Macroteleia Westwood (Hymenoptera, Platygastridae s. l., Scelioninae) from China

Chen HY, Johnson NF, Masner L, Xu ZF

Zookeys, 2013.
PMID: 23794890 DOI: 10.3897/zookeys.300.4934

The genus Macroteleia Westwood (Hymenoptera: Platygastridaes. l., Scelioninae) from China is revised. Seventeen species are recognized based on 502 specimens, all of which are new records for China. Seven new species are described: Macroteleia carinigena sp. n. (China), Macroteleia flava sp. n. (China), Macroteleia gracilis sp. n. (China), Macroteleia salebrosa sp. n. (China), Macroteleia semicircula sp. n. (China), Macroteleia spinitibia sp. n. (China) and Macroteleia striatipleuron sp. n. (China). Ten species are redescribed: Macroteleia boriviliensis Saraswat (China, India, Thailand), Macroteleia crawfordi Kiefer, stat. n. (China, Philippines, Thailand, Vietnam), Macroteleia dolichopa Sharma (China, India, Vietnam), Macroteleia emarginata Dodd (China, Malaysia), Macroteleia indica Saraswat & Sharma (China, India, Vietnam), Macroteleia lamba Saraswat & Sharma (China, India, Thailand, Vietnam), Macroteleia livingstoni Saraswat (China, India), Macroteleia peliades Kozlov & Lê (China, Vietnam), Macroteleia rufa Szelényi (China, Egypt, Georgia, Russia, Thailand, Ukraine) and Macroteleia striativentris Crawford (China, Philippines, Thailand, Vietnam). The following five new synonyms are proposed: Macroteleia crates Kozlov & Lê syn. n. and Macroteleia demades Kozlov & Lê syn. n. of Macroteleia crawfordi Kieffer; Macroteleia cebes Kozlov & Lê syn. n. and Macroteleia dones Kozlov & Lê syn. n. of Macroteleia indica Saraswat & Sharma; Macroteleia dores Kozlov & Lê syn. n. of Macroteleia lamba Saraswat & Sharma. A key to the Chinese species of the genus is provided.

Matched MeSH terms: Ukraine
Fulltext Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study

Tan J, Altice FL, Madden LM, Zelenev A

Lancet HIV, 2020 02;7(2):e121-e128.
PMID: 31879250 DOI: 10.1016/S2352-3018(19)30373-X

BACKGROUND: As HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverage among PWID, we did an optimisation assessment using current OAT procurement and allocation, then modelled the effect of increased OAT scale-up on HIV incidence and mortality for 23 administrative regions of Ukraine.
METHODS: We developed a linear optimisation model to estimate efficiency gains that could be achieved based on current procurement of OAT. We also developed a dynamic, compartmental population model of HIV transmission that included both injection and sexual risk to estimate the effect of OAT scale-up on HIV infections and mortality over a 10-year horizon. The compartmental population model was calibrated to HIV prevalence and incidence among PWID for 23 administrative regions of Ukraine. Sources for regional data included the SyrEx database, the Integrated Biological and Behavioral Survey, the Ukrainian Center for Socially Dangerous Disease Control of the Ministry of Health of Ukraine, the Public Health Center of the Ministry of Health of Ukraine, and the Ukrainian Census.
FINDINGS: Under a status-quo scenario (OAT coverage of 2·7% among PWID), the number of new HIV infections among PWID in Ukraine over the next 10 years was projected to increase to 58 820 (95% CI 47 968-65 535), with striking regional differences. With optimum allocation of OAT without additional increases in procurement, OAT coverage could increase from 2·7% to 3·3% by increasing OAT doses to ensure higher retention levels. OAT scale-up to 10% and 20% over 10 years would, respectively, prevent 4368 (95% CI 3134-5243) and 10 864 (7787-13 038) new HIV infections and reduce deaths by 7096 (95% CI 5078-9160) and 17 863 (12 828-23 062), relative to the status quo. OAT expansion to 20% in five regions of Ukraine with the highest HIV burden would account for 56% of new HIV infections and 49% of deaths prevented over 10 years.
INTERPRETATION: To optimise HIV prevention and treatment goals in Ukraine, OAT must be substantially scaled up in all regions. Increased medication procurement is needed, combined with optimisation of OAT dosing. Restricting OAT scale-up to some regions of Ukraine could benefit many PWID, but the regions most affected are not necessarily those with the highest HIV burden.
FUNDING: National Institute on Drug Abuse.

Matched MeSH terms: Ukraine/epidemiology
Management of Dyslipidemia in Individuals with Low-to-Moderate Cardiovascular Risk: Role of Nutraceuticals

Dolzhenko MM, Barnett OY, Grassos C, Dragomiretska NV, Goloborodko BI, Ilashchuk TO, et al.

Adv Ther, 2020 11;37(11):4549-4567.
PMID: 32979190 DOI: 10.1007/s12325-020-01490-z

Cardiovascular diseases (CVDs) are the leading cause of premature deaths globally and in Ukraine. Dyslipidemia is a recognized risk factor for the development of CVD. Therefore, early detection and appropriate management of dyslipidemia are essential for the primary prevention of CVDs. However, currently, there is a lack of Ukraine-specific guideline recommendations focusing on the management of dyslipidemia in individuals with low-to-moderate CV risk, thus creating an urgent need for structured and easily implementable clinical recommendations/guidelines specific to the country. An expert panel of cardiologists, endocrinologists, and family physicians convened in Ukraine in March 2019. The expert panel critically reviewed and analyzed the current literature and put forth the following recommendations for the management of dyslipidemia in individuals with low-to-moderate risk of CVDs specific to Ukraine: (1) family physicians have the greatest opportunities in carrying out primary prevention; (2) lipid-lowering interventions are essential for primary prevention as per guidelines; (3) a number of nutraceuticals and nutraceutical combinations with clinically established lipid-lowering properties can be considered for primary prevention; they also have a suggested role as an alternative therapy for statin-intolerant patients; (4) on the basis of clinical evidence, nutraceuticals are suggested by guidelines for primary prevention; (5) red yeast rice has potent CV-risk-lowering potential, in addition to lipid-lowering properties; (6) in patients with low-to-moderate cardiovascular risk, a nutraceutical combination of low-dose red yeast rice and synergic lipid-lowering compounds can be used as integral part of guideline-recommended lifestyle interventions for effective primary prevention strategy; (7) nutraceutical combination can be used in patients aged 18 to 75+ years; its use is particularly appropriate in the age group of 18-44 years; (8) it is necessary to attract the media (websites, etc.) to increase patient awareness on the importance of primary prevention; and (9) it is necessary to legally separate nutraceuticals from dietary supplements. These consensus recommendations will help physicians in Ukraine effectively manage dyslipidemia in individuals with low-to-moderate CV risk.

Matched MeSH terms: Ukraine